NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories announced a quarterly dividend on Friday, June 8th. Investors of record on Friday, July 13th will be given a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date of this dividend is Thursday, July 12th. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Wednesday, July, 18th. The healthcare product maker reported $0.73 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.71 by $0.02. The healthcare product maker earned $7.77 billion during the quarter, compared to analysts' expectations of $7.71 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.54%. The firm's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories updated its FY18 earnings guidance on Wednesday, July, 18th. The company provided earnings per share guidance of $2.85-2.91 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86. Abbott Laboratories also updated its Q3 guidance to $0.73-0.75 EPS.

18 brokerages have issued 12 month price targets for Abbott Laboratories' stock. Their predictions range from $64.00 to $80.00. On average, they expect Abbott Laboratories' share price to reach $69.50 in the next year. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Ratings for Abbott Laboratories.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Media coverage about ABT stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.10 on Accern's scale. They also gave headlines about the healthcare product maker an impact score of 45.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.12%), Swedbank (0.09%), Retirement Systems of Alabama (0.09%), Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%) and Welch & Forbes LLC (0.04%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bank of Montreal Can, Palo Capital Inc., Deprince Race & Zollo Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Rathbone Brothers plc, Mckinley Capital Management LLC Delaware and Oakbrook Investments LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was purchased by a variety of institutional investors in the last quarter, including Swedbank, Atalanta Sosnoff Capital LLC, Dalton Greiner Hartman Maher & Co., Contravisory Investment Management Inc., State of Alaska Department of Revenue, Calamos Advisors LLC, Ipswich Investment Management Co. Inc. and IFM Investors Pty Ltd. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $64.75.

Abbott Laboratories has a market capitalization of $110.10 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.